Literature DB >> 16138267

Pharmacological PPARgamma stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes.

T Forst1, C Hohberg, S D Fuellert, G Lübben, T Konrad, M Löbig, M M Weber, C Sachara, V Gottschall, A Pfützner.   

Abstract

The role of intact proinsulin and adiponectin in endothelial dysfunction and insulin resistance has been receiving increasing attention. This study investigates the effect of PPARgamma stimulation or beta-cell stimulation on metabolic and vascular parameters in patients with type 2 diabetes. In our study, 173 type 2 diabetic patients were recruited and randomly assigned to pioglitazone 45 mg or glimepiride 1 - 6 mg treatment. Intima media thickness of the carotid artery, glycemic control, insulin resistance, adiponectin and intact proinsulin levels were assessed at baseline and after six months of treatment. Despite similar improvements in metabolic control (HbA (1c) after 24 weeks: - 0.8 +/- 0.9% [pioglitazone] vs. - 0.6 +/- 0.8% [glimepiride]; mean +/- SD; p < 0.0001, respectively), improvements in intima media thickness (- 0.033 +/- 0.052 mm; p < 0.0001), proinsulin intact (- 5.92 +/- 10.04 pmol/l; p < 0.0001), adiponectin (10.9 +/- 6.3 microg/ml; p < 0.0001) and HOMA score (- 2.21 +/- 3.40; p < 0.0001) were observed by pioglitazone but not glimepiride treatment. Reduction in intima media thickness was correlated with improved insulin sensitivity (r = 0.29; p = 0.0003), and proinsulin intact levels (r = 0.22; p = 0.006), while an inverse correlation was found with adiponectin levels (r = - 0.37; p < 0.0001). Measurement of adiponectin and intact proinsulin enables characterization of the metabolic situation and an estimation of atherosclerotic risk in patients with type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16138267     DOI: 10.1055/s-2005-870322

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  11 in total

Review 1.  Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents.

Authors:  Giuseppe Derosa
Journal:  Drugs       Date:  2010-10-22       Impact factor: 9.546

Review 2.  Elevated intact proinsulin levels are indicative of Beta-cell dysfunction, insulin resistance, and cardiovascular risk: impact of the antidiabetic agent pioglitazone.

Authors:  Andreas Pfützner; Thomas Forst
Journal:  J Diabetes Sci Technol       Date:  2011-05-01

3.  Impact of pioglitazone on coronary endothelial function in non-diabetic patients with coronary artery disease.

Authors:  Jochen Wöhrle; Nikolaus Marx; Wolfgang Koenig; Vinzenz Hombach; Hans A Kestler; Martin Höher; Thorsten Nusser
Journal:  Clin Res Cardiol       Date:  2008-04-24       Impact factor: 5.460

4.  Pioglitazone opposes neurogenic vascular dysfunction associated with chronic hyperinsulinaemia.

Authors:  S Takatori; Y Zamami; N Yabumae; N Hanafusa; M Mio; T Egawa; H Kawasaki
Journal:  Br J Pharmacol       Date:  2008-02-04       Impact factor: 8.739

Review 5.  Pioglitazone for type 2 diabetes mellitus.

Authors:  B Richter; E Bandeira-Echtler; K Bergerhoff; C Clar; S H Ebrahim
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

6.  Risk management in the treatment of type 2 diabetes with pioglitazone.

Authors:  Giuseppe Derosa; Sibilla At Salvadeo
Journal:  Diabetes Metab Syndr Obes       Date:  2009-07-01       Impact factor: 3.168

7.  The effects of pioglitazone in reducing atherosclerosis progression and neointima volume in type 2 diabetic patients: prospective randomized study with volumetric intravascular ultrasonography analysis.

Authors:  Sung Hye You; Beum Suk Kim; Soon Jun Hong; Chul-Min Ahn; Do-Sun Lim
Journal:  Korean Circ J       Date:  2010-12-31       Impact factor: 3.243

8.  Downregulation of the proinflammatory state of circulating mononuclear cells by short-term treatment with pioglitazone in patients with type 2 diabetes mellitus and coronary artery disease.

Authors:  Andreas Pfützner; Alexander Weise; Elisabeth Pfützner-Riehn; Georg Lübben; Michael Morcos; Efstrathios Karagiannis; Matthias Weber; Thomas Forst
Journal:  PPAR Res       Date:  2011-07-26       Impact factor: 4.964

Review 9.  Cardiovascular benefits of GLP-1-based herapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control.

Authors:  Thomas Forst; Matthias M Weber; Andreas Pfützner
Journal:  Exp Diabetes Res       Date:  2012-04-17

Review 10.  A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes.

Authors:  Mozhgan Dorkhan; Anders Frid
Journal:  Vasc Health Risk Manag       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.